Apogee Therapeutics CEO Michael Henderson sells shares value $698,653

In a latest transaction, Michael Henderson, the Chief Govt Officer of Apogee (NASDAQ:APOG) Therapeutics, Inc. (NASDAQ:APGE), offered shares of the corporate’s widespread inventory totaling roughly $698,653. The gross sales, which occurred on December 4, had been executed beneath a Rule 10b5-1 buying and selling plan adopted on September 25, 2023. The transaction comes as the corporate’s inventory has proven exceptional power, posting a 130% achieve over the previous yr, based on InvestingPro knowledge.

The transactions concerned the sale of 13,328 shares at a weighted common value inside the vary of $46.00 to $46.98, and a further 1,672 shares at a weighted common value between $47.00 and $47.275. Following these gross sales, Henderson retains possession of 1,324,487 shares of Apogee Therapeutics.

These transactions mirror routine monetary administration and planning by the CEO, carried out beneath a pre-established buying and selling plan.

In different latest information, Apogee Therapeutics has seen a sequence of optimistic developments. Guggenheim maintains a Purchase score on Apogee, lifting the worth goal to $110 from $95, primarily based on promising analysis and improvement methods. The agency additionally anticipates a major progress within the TH2 market, which Apogee targets, probably doubling to over $50 billion by 2030.

Apogee has reported promising outcomes from its ongoing Section 1 scientific trial of APG777, a remedy for moderate-to-severe atopic dermatitis, and initiated a Section 1 trial for APG990. Moreover, Stifel maintained its Purchase score on Apogee, emphasizing the potential of APG777 and upcoming milestones in 2025.

The corporate’s monetary place stays robust, with $790 million in property anticipated to assist the continued improvement of its pipeline into 2028. Lastly, Apogee has welcomed Jeff S. Hartness as its new Chief Industrial Officer and Dr. Lisa Bollinger to its board of administrators, highlighting the corporate’s company progress. These are the latest developments at Apogee Therapeutics.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.